MiNK Therapeutics
INKT
21 hedge funds and large institutions have $5.96M invested in MiNK Therapeutics in 2021 Q4 according to their latest regulatory filings, with 21 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
0.4% more ownership
Funds ownership: 0% → 0.4% (+0.4%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RI
RTW Investments
New York
|
+$4.95M |
| 2 |
SI
Sofinnova Investments
Menlo Park,
California
|
+$4.11M |
| 3 |
AG
Artal Group
Luxembourg
|
+$3.44M |
| 4 |
Millennium Management
New York
|
+$815K |
| 5 |
Morgan Stanley
New York
|
+$506K |
Top Sellers
INKT Hedge Fund Activity: Q4 2021 in Review
21 of the 6,499 institutional investors tracked by Wall St. Rank reported a position in MiNK Therapeutics (INKT) for Q4 2021, worth a combined $5.96M.
Buyers outnumbered sellers: 21 funds opened new INKT positions and 0 closed out — a net gain of 21 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was RTW Investments, opening a new position worth an estimated $4.95M.
- 21 institutional investors held MiNK Therapeutics (INKT) as of Q4 2021, up from 0 in Q3 2021.
- Funds reported $5.96M of MiNK Therapeutics stock for Q4 2021.
- 21 funds opened new MiNK Therapeutics positions in Q4 2021 and 0 closed out, a net change of +21 holders.
- The largest MiNK Therapeutics buyer in Q4 2021 was RTW Investments, an estimated $4.95M added.
Based on aggregated 13F filings for Q4 2021.